Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 4;15(1):57.
doi: 10.1038/s41408-025-01264-2.

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

Abiola Bolarinwa  1 , Madhu Nagaraj  1 , Saurabh Zanwar  1 , Nadine Abdallah  1 , P Leif Bergsagel  2 , Moritz Binder  1 , Francis Buadi  1 , Saurabh Chhabra  2 , Joselle Cook  1 , David Dingli  1 , Angela Dispenzieri  1 , Morie A Gertz  1 , Wilson Gonsalves  1 , Suzanne Hayman  1 , Prashant Kapoor  1 , Taxiarchis Kourelis  1 , Nelson Leung  1 , Yi Lin  1 , Eli Muchtar  1 , Ricardo Parrondo  3 , Vivek Roy  3 , Taimur Sher  3 , Mustaqeem Siddiqui  1 , Rahma Warsame  1 , Amie Fonder  1 , Miriam Hobbs  1 , Yi Lisa Hwa  1 , Michelle Rogers  1 , Udit Yadav  2 , J Erin Wiedmeier-Nutor  2 , Linda B Baughn  4 , S Vincent Rajkumar  1 , Rafael Fonseca  2 , Sikander Ailawadhi  3 , Shaji Kumar  5
Affiliations

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

Abiola Bolarinwa et al. Blood Cancer J. .

Abstract

Venetoclax (Ven), a BCL-2 inhibitor, has demonstrated efficacy in patients with relapsed/refractory multiple myeloma (RRMM) harboring a t(11;14) and/or elevated BCL-2 expression. However, data from clinical trial remain inconclusive. This retrospective study evaluated the efficacy and safety of Ven-based therapies in 232 MM patients without concurrent AL amyloidosis treated at Mayo Clinic sites between Jan 2015 and Dec 2023. The median age was 62 years, with a median of 3 prior lines of therapy. Among the cohort, 82% had t(11;14), and elevated BCL-2 expression was identified in 17 of 18 non-t(11;14) patients tested. Ven combinations included Ven-Dex (VenD; 48.3%), Proteasome Inhibitor-Ven (30.2%), and Daratumumab-Ven (19%) with other combinations making up the rest. The overall response rate was 57%; 64% for t(11;14) patients and 26% for non-t(11;14) patients. Median progression-free survival (PFS) was 9.4 months overall; 11.8 months for t(11;14) patients and 2.9 months for those without (p < 0.001). Among t(11;14) patients, the presence of del(17p) or 1q gain/amplification significantly reduced PFS to 7.7 months. Venetoclax-based regimens remain an important option for t(11;14) patients, but efficacy is limited in patients without a t(11;14). The presence of secondary high-risk cytogenetics imparts an inferior PFS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors report to conflicts of interest pertaining to the submitted work. PLB: Novartis: Research Funding; Omeros: Consultancy; Oncopeptides: Consultancy; BMS/Celgene: Research Funding; Pfizer: Research Funding; Cellcentric: Consultancy; Janssen: Consultancy; Sanofi: Research Funding. SC: GlaxoSmithKline, Sanofi: Honoraria; Omeros: Speakers Bureau; Bristol Myers Squibb, Amgen, Janssen, Novartis, Syndax, Ionis, Sanofi, and GlaxoSmithKline: Research Funding. JC: Geron Corp: Other: Held $600 Geron Stock for 1 week and sold without profit. DD: Apellis: Consultancy, Honoraria, Research Funding; K36 Therapeutics: Research Funding; Sanofi: Consultancy, Honoraria; BMS: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sorrento: Consultancy, Honoraria; Genentech: Consultancy; Janssen: Consultancy, Honoraria; Alexion: Consultancy, Honoraria. AD: Alexion: Consultancy, Research Funding; Janssen: Research Funding; HaemaloiX: Research Funding; Takeda: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Alnylam: Research Funding; Pfizer: Research Funding. MAG: Astra Zeneca: Honoraria; Alexion: Honoraria; Abbvie: Other: personal fees for Data Safety Monitoring board ; Prothena: Other: personal fees; Sanofi: Other: personal fees; Ionis/Akcea: Honoraria; Alnylym: Honoraria; Johnson & Johnson: Other: personal fees; Medscape: Honoraria; Janssen: Other: personal fees; Dava Oncology: Honoraria. PK: AbbVie: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Kite: Membership on an entity’s Board of Directors or advisory committees; Ichnos: Research Funding; Mustang Bio: Membership on an entity’s Board of Directors or advisory committees; Keosys: Consultancy; Loxo Pharmaceuticals: Research Funding; Angitia Bio: Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Membership on an entity’s Board of Directors or advisory committees; CVS Caremark: Consultancy; Janssen: Membership on an entity’s Board of Directors or advisory committees; Karyopharm: Research Funding; X4 Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Sanofi: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Pharmacyclics: Membership on an entity’s Board of Directors or advisory committees; BeiGene: Membership on an entity’s Board of Directors or advisory committees, Research Funding; GlaxoSmithKline: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Research Funding; Regeneron: Research Funding; Amgen: Research Funding. TK: Novartis: Research Funding; Pfizer: Research Funding. NL: AbbVie: Current holder of stock options in a privately-held company; Checkpoint Therapeutics: Current holder of stock options in a privately-held company. YL: Pfizer: Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Caribou: Membership on an entity’s Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; NexImmune: Membership on an entity’s Board of Directors or advisory committees; Legend: Consultancy; Regeneron: Consultancy; Genentech: Consultancy. EM: Protego: Consultancy. RP: Bristol Myers Squibb, GSK: Research Funding; Sanofi Aventis: Honoraria; AstraZeneca: Honoraria. TS: Caelum pharma: Other; Alpha: Consultancy, Membership on an entity’s Board of Directors or advisory committees; 2 Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Prothena: Other. YLH: GSK: Honoraria; Janssen: Honoraria; Shield Therapeutics: Honoraria; MultiMedia Medical, LLC: Consultancy; Pfizer: Other: Consulting fee located to Mayo Research fund. LBB: Genentech: Consultancy. RF: AbbVie, Adaptive, Amgen, Apple, Bayer, BMS/Celgene, Gilead, GSK, Janssen, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Arduro Biotech, Oncotracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, Sanofi: Consultancy; Patent for FISH in MM - ~$2000/year: Patents & Royalties: Patent for FISH in MM - ~$2000/year; Antengene: Membership on an entity’s Board of Directors or advisory committees; Celgene, Bristol Myers Squibb, Bayer, Amgen, Janssen, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi, OncoTracker: Honoraria. SA: Xencor: Research Funding; Janssen: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Cellectar: Consultancy, Honoraria, Research Funding; Abbvie: Research Funding; Ascentage: Research Funding; GSK: Consultancy, Research Funding; Sanofi: Consultancy; BMS: Consultancy, Research Funding; Johnson and Johnson: Consultancy, Research Funding; Regeneron: Consultancy; Beigene: Consultancy; Takeda: Consultancy; Pharmacuclics: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding. SK: Abbvie: Membership on an entity’s Board of Directors or advisory committees, Research Funding; MedImmune/AstraZeneca: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Takeda: Membership on an entity’s Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Roche: Research Funding; Sanofi: Research Funding; Oncopeptides: Other: Independent review committee participation.

Figures

Fig. 1
Fig. 1
Progression Free Survival in patients with t(11;14) vs non-t(11;14): Patients with t(11;14) demonstrated a significantly better median PFS of 11.8 months for t(11;14) patients and 2.9 months for those without t(11;14), p < 0.0001.
Fig. 2
Fig. 2
Impact of Secondary cytogenetic abnormalities in t(11;14): In patients with t(11;14), presence of 1q gain/amplification/ del(17p) is associated with inferior progression free survival (PFS), median PFS 7.7 months vs. 15.1 months, p = 0.013.
See this image and copyright information in PMC

References

    1. Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801–8. - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013;25:28. - PMC - PubMed
    1. Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401–9. - PubMed
    1. Mateos M-V, Moreau P, Dimopoulos MA, Hong W-J, Cooper S, Yu Y, et al. A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. J Clin Oncol. 2020;20;38.
    1. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130:2392–400. - PubMed

MeSH terms